ACT-777991

• UNSPSC Description:

  ACT-777991 is an orally active and selective CXCR3 antagonist. ACT-777991 has microsomes and hepatocytes stability across animal models. ACT-777991 inhibits the migration of activated T cells toward CXCL11[1].

• Target Antigen:

  CXCR

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein;Immunology/Inflammation

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/act-777991.html

• Solubility:

  10 mM in DMSO

• Smiles:

  OCC[C@@H](N(C(CN1C=NC(C)=N1)=O)CC2)CN2C(SC(C(F)(F)F)=N3)=C3C4=CN=C(C(F)(F)F)N=C4

• Molecular Weight:

  550.48

• References & Citations:

  [1]Meyer EA, et al. Discovery of Clinical Candidate ACT-777991, a Potent CXCR3 Antagonist for Antigen-Driven and Inflammatory Pathologies. J Med Chem. 2023 Mar 23;66(6):4179-4196.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  Phase 1

• CAS Number:

  1967811-46-6